Australia's most trusted
source of pharma news
Posted 11 February 2026 AM
Sanofi’s Beyfortus could trigger a change in how new and emerging therapies are subsidised in Australia, with a bill introduced to expand the definition of ‘vaccine’ under the National Health Act 1953.
It comes after the PBAC deferred making a recommendation in May 2025 to list Beyfortus on the National Immunisation Program (NIP) for the prevention of RSV lower respiratory tract disease in neonates and infants born during or entering their first RSV season; and children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.